Sulfargin ointment, 50 g

• Treatment of infected burn wounds,

• bedsores

• abrasions

• skin ulcers

• transplanted skin areas;

• as well as to prevent their infection.

Apply externally (under a bandage or open method) 1-2 times / day. The maximum single dose is 300 g. The duration of treatment is set individually, depends on the nature of the disease and the effectiveness of the treatment used and, as a rule, is up to 3 weeks.

Ointment for external use is white or almost white in color, with a characteristic odor.

1 g silver sulfadiazine 10 mg

Excipients: liquid paraffin - 230 mg, propylene glycol - 100 mg, cetostearyl alcohol - 60 mg, glyceryl monostearate 40-55 - 30 mg, polysorbate 80 - 20 mg, methyl parahydroxybenzoate - 0.8 mg, propyl parahydroxybenzoate - 0.2 mg, purified water - up to 1 g.

Pregnancy, hypersensitivity to silver sulfadiazine.

Do not use in newborns.

pharmachologic effect

Broad-spectrum antimicrobial agent, sulfanilamide. Silver sulfadiazine is active against gram-positive and gram-negative bacteria (Escherichia coli, Proteus spp., Staphylococcus spp., Klebsiella spp.). Bactericidal properties are due to the activity of silver ions, which are released in the wound as a result of the dissociation of the silver salt of sulfadiazine; the release of silver ions occurs gradually (moderate dissociation), ensuring the constancy of the antimicrobial action. The bactericidal activity of silver ions is complemented by the bacteriostatic effect of sulfadiazine (also released during the dissociation of the silver salt of sulfadiazine).

Pharmacokinetics

When applied to the wound surface, about 10% sulfadiazine and 1% silver are absorbed into the peripheral and systemic circulation. Application to an extensive wound surface is accompanied by an increase in the concentration of sulfadiazine in the blood up to 10-20 ?g / ml.

Side effect

Local reactions: burning and itching at the site of application, violation of skin pigmentation, skin allergic reactions, skin necrosis. Systemic reactions: erythema multiforme, interstitial nephritis, leukopenia, which is characterized mainly by a decrease in the number of neutrophils. The maximum decrease in the number of leukocytes is observed 2-4 days after the start of treatment; the normalization of the number of leukocytes is observed for 2-4 days, while the continuation of treatment does not affect the process of restoring the number of leukocytes. With prolonged use on large wound surfaces: systemic side effects typical for sulfonamides, incl. violation of hematopoiesis (agranulocytosis, aplastic and hemolytic anemia, thrombocytopenia, leukopenia), skin and allergic reactions, incl. Stevens-Johnson syndrome and exfoliative dermatitis; dyspepsia, hepatitis,hepatocellular necrosis, dysfunction of the central nervous system and toxic nephrosis. The degree of absorption depends on the size of the burn area and the degree of tissue damage.

Application during pregnancy and lactation

Contraindicated in pregnancy.

Application for violations of liver function

When treating patients with impaired liver function, it is necessary to regularly monitor the content of sulfadiazine in the blood plasma.

Application for impaired renal function

When treating patients with impaired renal function, it is necessary to regularly monitor the content of sulfadiazine in the blood plasma.

Application in children

Not for use in newborns

special instructions

When treating patients with impaired liver and kidney function, it is necessary to regularly monitor the content of sulfadiazine in the blood plasma.